Terminated × Interventional × Myelodysplastic Syndromes × Clear all Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Phase 1 Terminated
106 enrolled 28 charts
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
Phase 2 Terminated
235 enrolled
FLUBUTBI
Phase 3 Terminated
53 enrolled 11 charts
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 Terminated
18 enrolled 19 charts
Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease
Phase 1 Terminated
4 enrolled
Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome
Phase 1/2 Terminated
51 enrolled
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Phase 1 Terminated
20 enrolled
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Phase 1 Terminated
28 enrolled 19 charts
STIMULUS-MDS2
Phase 3 Terminated
530 enrolled 29 charts
First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Phase 1/2 Terminated
101 enrolled
Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes
Phase 1/2 Terminated
3 enrolled 9 charts
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
Phase 1 Terminated
25 enrolled
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
Phase 1/2 Terminated
24 enrolled 15 charts
LIMBER
Phase 1/2 Terminated
22 enrolled 28 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
Phase 1/2 Terminated
13 enrolled
ACHIEVE
Phase 2 Terminated
16 enrolled
A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Phase 1 Terminated
56 enrolled 24 charts
5
Phase 2 Terminated
10 enrolled
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
Phase 1/2 Terminated
67 enrolled
AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia
Phase 1 Terminated
7 enrolled 16 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
Phase 1 Terminated
101 enrolled 54 charts
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Phase 1 Terminated
16 enrolled 13 charts
UF-BMT-LDND-101
Phase 3 Terminated
217 enrolled
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
Phase 2 Terminated
53 enrolled
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies
Phase 2 Terminated
7 enrolled 12 charts
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS
Phase 1 Terminated
7 enrolled
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
Phase 1/2 Terminated
48 enrolled
A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
Phase 1 Terminated
68 enrolled
A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies
Phase 1 Terminated
95 enrolled 47 charts
LAUREL
Phase 1 Terminated
2 enrolled
A Study of ONO-7475 in Patients With Acute Leukemias
Phase 1/2 Terminated
42 enrolled 47 charts
Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide
Phase 2 Terminated
5 enrolled
IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome
Phase 1/2 Terminated
2 enrolled 14 charts
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1 Terminated
37 enrolled 14 charts
Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Phase 1 Terminated
39 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
Phase 1 Terminated
40 enrolled
Encore-MDS
Phase 1 Terminated
127 enrolled
IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia
Phase 2 Terminated
43 enrolled 14 charts
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Phase 1 Terminated
21 enrolled
A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS
Phase 1/2 Terminated
20 enrolled 13 charts
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Phase 1/2 Terminated
4 enrolled 9 charts
THRIVE
Phase 2/3 Terminated
1 enrolled 9 charts
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Phase 1/2 Terminated
187 enrolled 8 charts